

MARKET RELEASE

Sale of shares by Kojent Pty Ltd to institutional shareholders

Melbourne, Australia, 17 November, 2021 – Medtech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) (ASX: MDR) announces it has been notified that Kojent Pty Ltd (**Kojent**) has sold 6,846,955 shares in the Company to institutional shareholders.

MedAdvisor director Mr Jim Xenos is a director of Kojent and a beneficiary of a trust on behalf of which Kojent holds shares in MedAdvisor.

Prior to the sale, a total of 20,540,866 shares in the Company were held by Kojent on trust for three beneficiaries. Kojent has advised it is selling the shares in the Company at the request of one the beneficiaries which is not otherwise associated with Mr Xenos or the Company. This represents one third of Kojent's holding. Mr Xenos has advised that Kojent has no current intention to sell any further shares in the Company.

Mr Xenos said, *"I remain fully committed to the Company and look forward to continuing to support MedAdvisor through this exciting growth phase."*

The share trade has been made in accordance with the Company's Share Trading Policy. Please see attached Appendix 3Y (Change of Director's Interest Notice) with respect to this change.

– ENDS –

This document has been authorised for release by Naomi Lawrie, MedAdvisor Company Secretary.

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers patients to simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 25,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 2.3 million patients through more than 65% of Australian pharmacies. MedAdvisor has partnered with Cotiviti in the US and is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors

For more information:

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 905 3036

Greer Quinn
Media relations
greer@forwardcomm.com.au
0433 753 557

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MEDADVISOR LIMITED
ABN	17 145 327 617

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jim Xenos
Date of last notice	21 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Kojent Pty Ltd (of which Mr Xenos is a director) as trustee of the Kojent Trust (of which Mr Xenos is a beneficiary)
Date of change	17 November 2021
No. of securities held prior to change	Direct: 42,857 fully paid ordinary shares Indirect: 20,540,866 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	Nil
Number disposed	6,846,955
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$2,464,903.80

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	Direct: 42,857 fully paid ordinary shares Indirect: 13,693,911 fully paid ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market sale of shares to institutional investors

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.